T 0980/19 of 19.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T098019.20211019
- Date of decision
- 19 October 2021
- Case number
- T 0980/19
- Petition for review of
- -
- Application number
- 10006835.2
- IPC class
- C07C 7/00C07K 5/08C07F 5/02A61P 35/00C07F 5/04C07K 5/06A61P 29/00A61K 38/05C07K 5/078A61K 38/00A61K 31/69C07K 7/02
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- T 0980/19 2022-04-27
- Abstracts for this decision
- -
- Application title
- FORMULATION OF BORONIC ACID COMPOUNDS
- Applicant name
- THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Opponent name
- HGF Limited
Pfizer Inc.
Accord Healthcare Ltd
LEK Pharmaceuticals d.d.
Synthon B.V.
Fresenius Kabi Deutschland GmbH
Pentafarma Sociedade Técnico-Medicinal S.A.
Generics (U.K.) Limited
Teva Pharmaceuticals Inc. - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 107European Patent Convention Art 112a(1)European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 76(1)European Patent Convention Art 83European Patent Convention R 106European Patent Convention R 80Rules of procedure of the Boards of Appeal Art 12(1)(a)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)Rules of procedure of the Boards of Appeal Art 25(3)
- Keywords
- Allegation of public prior use and accompanying evidence - filed for the first time in appeal
Inventive step
Sufficiency of disclosure
Amendments
Request to continue proceeding in writing
Objection under Rule 106 EPC - Catchword
- -
- Cited cases
- R 0009/14T 0152/03T 0952/06T 0007/07T 0724/08T 0406/09T 0518/10T 0691/12T 1348/14T 0239/16T 1711/16
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description to be adapted thereto:
Claim 1 of auxiliary request 1, filed with the statement of grounds of appeal.